Sexually Transmitted Diseases

Jake Glaser discusses how generating interest for the response to HIV and AIDS has changed since the 1990s.

Due to concerns that the use of PrEP might hinder clinicians from detecting HIV in infected individuals or lead to the development of resistant strains of HIV, scientists studied how PrEP affects seroconversion after HIV is acquired.

A phase 2a clinical trial has found the dapivirine vaginal ring to be a safe and acceptable means for HIV prevention in adolescents, who showed notably high adherence when using the ring.

The NIH has released the findings of the first of 2 early-stage clinical trials on assessing the safety and effectiveness of HIV candidate vaccinations that support additional development of vaccines.

As the IAS Conference on HIV Science wraps up this week, this Public Health Watch report takes a closer look at the challenges that remain when it comes to treating HIV.

Phase 2 study finds that the use of daily oral Truvada as a means of HIV prevention is safe and acceptable.

Peter Williams, PhD, discusses the LATTE-2 trial for HIV treatment.

Magda Opsomer, MD, explains why darunavir may be more beneficial than other HIV medications.

Researchers reported at the 9th IAS Conference on HIV Science that a HIV-infected child who had been treated in infancy has maintained remission without drugs since 2008.

Ariane van der Straten, PhD, MPH, explains the different attributes of administering pre-exposure prophylaxis via a HIV biomedical implant.

A recent study finds that the majority of HIV-infected transgender women are anxious about taking ART and feminizing hormone therapy simultaneously due to hazardous drug interactions.

Leah Johnson, PhD, discusses the biomedical HIV prevention implant that is being developed by RTI International.

Kenneth Mayer, MD, explains why tenofovir alafenamide may be the future of pre-exposure prophylaxis.

WHO and IAS come together to create the first-ever global research prioritization agendas at the 9th IAS Conference on HIV Science in Paris, France.

The results of a phase 2 trial for a 2-drug regimen of long-acting cabotegravir and rilpivirine and a 3-drug regimen in patient with HIV showed comparable viral suppression rates at 96 weeks.

Researchers from Dartmouth College’s Geisel School of Medicine have found that pregnant women with a history of HSV-1 maintain active antibodies against the virus that can be passed on to their newborns.

The World Health Organization (WHO) recently sent out a global alert warning of the growing threat of resistance to HIV drugs.

A systematic review analyzes the opportunity to provide coordinated care for HIV and noncommunicable conditions.

Women with HIV are at higher risk of having potentially cancer-causing HPV in their anal canals, raising questions about how best to screen this population.

A study published in Oxford University Press evaluates the effectiveness of several HIV diagnostic tests.

Kenneth Mayer, MD, discusses new therapies that may have a positive impact on pre-exposure prophylaxis adherence and treatment.

A new iteration of the American Health Care Act (AHCA), the challenge of sepsis in US hospitals, a predictive map that identifies which species are likely to harbor the next human virus, how one Canadian researcher mail-ordered his way to horsepox, and a focus on how gonorrhea is on the way to becoming untreatable comprise the top 5 articles of the week for the week.

New research suggests that a vaccine designed to protect against meningitis may also protect against gonorrhea infections.

Although advances in HIV treatment mean many people with the condition are able to achieve viral suppression and display no outward signs of illness, kidney disease is still a fairly common occurrence in those who are infected.

The National Institutes of Health (NIH) is looking to determine whether Zika virus infection poses an additional risk in women whose pregnancies are already complicated by HIV.

A group of researchers examine the feasibility of a low-resource behavioral intervention created to promote retention in HIV care.

In a new study from Amsterdam, researchers have found that patients who were recently treated with azithromycin showed increased resistance to treatment for Neisseria gonorrhoeae.

A look into how health information exchange interventions are beneficial in HIV care; the discovery of 3 mutations that could help the bird flu spread among humans; news about a new patch formulation for the flu vaccine; progress towards an HIV vaccine; and information on an interactive map that visualizes the US HIV epidemic, make up the Top 5 articles for this week.

Following a request from the US Food and Drug Administration (FDA), Endo Pharmaceuticals has pulled its opioid agonist Opana ER (oxymorphone hydrochloride extended release).

The number of RSV-infected adults in an African study who also had HIV was quite high, with the burden of HIV disproportionately in the young.